Ilya Pharma has announced that the Indian Patent Office (IPO) has issued the Company Patent titled “Methods for Wound Healing”.
The patent covers the general use of a plasmid capable of expressing the protein CXCL12 in L. reuteri. The modified bacteria may be used for treatment of both mucosal and cutaneous wounds in humans and animals. These claims protect inventions which are central to the company’s programs for treating human and animal wounds and follow the awards of related US patent and EU patents.
“Our approach is attracting increasing interest because of both the low cost of manufacture and excellent temperature stability.”
“We are delighted to have received this patent in India, being an important market, to add to our increasingly robust patent portfolio. Our approach is attracting increasing interest because of both the low cost of manufacture and excellent temperature stability. As stated previously, we believe that this patent further supports the recognition of the therapeutic utility of genetically modified bacteria in the “bugs for drugs” debate,” says CEO and Co-Founder Evelina Vågesjö.
Photo of Evelina Vågesjö: Jenny Öhman/Nordic Life Science